Filing summary
Entity and period: The supplied filing is Nuvilex, Inc.’s unaudited Form 10-Q for the quarter ended January 31, 2012, covering the three and nine months ended on that date. This does not match the request metadata naming Pharmacyte Biotech, Inc.; verify the issuer and filing before relying on this summary.
Financial performance
| Metric | Three months ended Jan. 31, 2012 | Nine months ended Jan. 31, 2012 | Prior-year comparable |
|---|---|---|---|
| Revenue | $20,271 | $59,877 | $32,022 and $74,851, respectively |
| Gross profit | $18,060 | $35,955 | $10,042 and $43,090, respectively |
| Gross margin | 89.1% | 60.0% | 31.4% and 57.6%, respectively |
| Operating expenses | $428,041 | $1,502,267 | $78,816 and $210,377, respectively |
| Operating loss | $(409,981) | $(1,466,312) | $(68,774) and $(167,287), respectively |
| Net loss | $(271,777) | $(1,394,949) | $(124,101) and $(304,180), respectively |
Revenue remained small and declined year over year. The nine-month net loss includes a reported $173,960 gain on debt forgiveness; the filing’s debt-settlement detail does not clearly reconcile to that amount. Operating expenses rose substantially, principally from stock-based compensation, restarting operations, and legal and professional costs. Nine-month compensation expense was $1,024,803, including $837,678 for officer shares not yet issued at period-end.
Cash flow, liquidity and debt
- Cash was $39,077 at January 31, 2012, down from $57,201 at April 30, 2011. Nine-month operating cash use was $207,334; investing cash use was $680,000, primarily acquisition-related; financing provided $869,210.
- Current assets were $751,907 and current liabilities $3,283,349. Their difference implies negative working capital of $2,531,442, while the going-concern note reports negative working capital of $2,779,376; the filing does not clearly reconcile the difference.
- The balance sheet reports $2,214,047 of short-term debt and $247,934 of long-term debt, alongside $356,254 accrued interest. The debt note’s maturity classification appears inconsistent with the balance sheet, so the exact current and long-term debt presentation should be verified.
- Stockholders’ deficit was $2,247,789, and accumulated deficit was $39,343,642. Common shares outstanding were 374,437,581 at March 20, 2012, versus 357,137,581 at April 30, 2011.
The balance sheet’s final “total liabilities and stockholders’ equity” is printed as negative $1,863,494, although total assets are positive $1,863,494. This appears inconsistent and should be checked against the filed financial statements.
Material changes, outlook and risks
- Management was pursuing an acquisition of SG Austria’s assets, including Austrianova Singapore and BioBlueBird, and funding pancreatic-cancer treatment development and related activities. The transaction was not complete at January 31; it required further funding and a share exchange. The filing says approximately $3 million was required under the original terms and reports $740,000 paid toward acquisition and related funding by February 29, 2012.
- Management described plans to control cash burn, seek funding, sell or lease the Freedom-2 property, resolve debts, and expand biotechnology operations. It gave no quantified revenue or earnings guidance and stated that continued operations depend on additional funding.
- The company disclosed substantial doubt about its ability to continue as a going concern, citing recurring losses, inadequate revenue, and negative working capital. It may need to curtail activities if funding is not obtained.
- Cornerstone Bank sued a subsidiary over a mortgage note and sought foreclosure on the Cherry Hill property, as well as enforcement of a claimed pledge of 14,605,614 common shares. Management said a loss of at least $750,000–$1 million was possible, with a worst case of full liability plus fees. A settlement was still being negotiated; the filing reports no clear estimated loss recognized for the claim.
- After quarter-end, the CEO loaned the company another $60,000; the company also reported a settlement with Avaya and CIT that relieved future obligations. These were subsequent events, not January 31 cash or debt balances.
- Management concluded internal control over financial reporting was ineffective, citing timely and accurate filing concerns. The filing also notes risks from additional capital needs, dilution, uncertain sales, competition, product and regulatory risks, and dependence on management and distribution channels.
Key facts for investors to verify
- Confirm that this Nuvilex filing is the intended issuer filing, given the Pharmacyte Biotech metadata mismatch.
- Reconcile the reported working-capital deficit, total liabilities and equity presentation, and debt current-versus-long-term classification.
- Confirm the amount and accounting for debt forgiveness, stock compensation, and shares payable or pledged as collateral.
- Check the status, total funding requirements, ownership/share-exchange terms, and completion conditions of the SG Austria transaction.
- Review developments in the Cornerstone Bank foreclosure and share-pledge dispute, including any settlement and resulting liabilities.
- Assess the company’s near-term funding runway, going-concern disclosures, and remediation of ineffective financial reporting controls.